CO2022012609A2 - Combinaciones de medicamento destinadas a inhibir la inflamación y activación de src quinasa después de procedimientos quirúrgicos invasivos - Google Patents

Combinaciones de medicamento destinadas a inhibir la inflamación y activación de src quinasa después de procedimientos quirúrgicos invasivos

Info

Publication number
CO2022012609A2
CO2022012609A2 CONC2022/0012609A CO2022012609A CO2022012609A2 CO 2022012609 A2 CO2022012609 A2 CO 2022012609A2 CO 2022012609 A CO2022012609 A CO 2022012609A CO 2022012609 A2 CO2022012609 A2 CO 2022012609A2
Authority
CO
Colombia
Prior art keywords
surgical procedures
invasive surgical
drug combinations
src kinase
kinase activation
Prior art date
Application number
CONC2022/0012609A
Other languages
English (en)
Inventor
Alain Borgeat
Augusto Mitidieri
Miro Venturi
Elisabetta Donati
E Gina Votta-Velis
Original Assignee
Sintetica S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sintetica S A filed Critical Sintetica S A
Publication of CO2022012609A2 publication Critical patent/CO2022012609A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Combinaciones de compuestos que inhiben la activación de p-Src tirosina quinasa, teniendo una utilidad par-ticular en el tratamiento de la inflamación causada por intervenciones quirúrgicas traumáticas y la proli-feración o metástasis de células cancerosas, después de la extirpación quirúrgica de tejido canceroso.
CONC2022/0012609A 2020-03-06 2022-09-05 Combinaciones de medicamento destinadas a inhibir la inflamación y activación de src quinasa después de procedimientos quirúrgicos invasivos CO2022012609A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062985962P 2020-03-06 2020-03-06
PCT/US2021/020674 WO2021178541A1 (en) 2020-03-06 2021-03-03 Drug combinations for inhibiting inflammation and src kinase activation following invasive surgical procedures

Publications (1)

Publication Number Publication Date
CO2022012609A2 true CO2022012609A2 (es) 2022-09-09

Family

ID=77614156

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0012609A CO2022012609A2 (es) 2020-03-06 2022-09-05 Combinaciones de medicamento destinadas a inhibir la inflamación y activación de src quinasa después de procedimientos quirúrgicos invasivos

Country Status (16)

Country Link
US (1) US20230158015A1 (es)
EP (1) EP4171535A4 (es)
JP (1) JP2023516090A (es)
KR (1) KR20220150371A (es)
CN (1) CN115315257A (es)
AR (1) AR121523A1 (es)
AU (1) AU2021232593A1 (es)
BR (1) BR112022017872A2 (es)
CA (1) CA3170998A1 (es)
CL (1) CL2022002424A1 (es)
CO (1) CO2022012609A2 (es)
IL (1) IL295824A (es)
MX (1) MX2022010995A (es)
TW (1) TW202139983A (es)
WO (1) WO2021178541A1 (es)
ZA (1) ZA202209901B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102863193B1 (ko) * 2023-03-13 2025-09-22 대구가톨릭대학교산학협력단 리도카인 유도체를 유효성분으로 포함하는 항염증용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054511A2 (en) * 2002-12-13 2004-07-01 The Regents Of The University Of California Analgesic combination comprising nalbuphine
EP1613324A2 (en) * 2003-04-14 2006-01-11 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
JP6686013B2 (ja) * 2014-10-17 2020-04-22 サリックス ファーマスーティカルズ，インコーポレーテッド 腫瘍の進行を減弱させるためのメチルナルトレキソンの使用

Also Published As

Publication number Publication date
EP4171535A1 (en) 2023-05-03
CN115315257A (zh) 2022-11-08
WO2021178541A1 (en) 2021-09-10
AU2021232593A1 (en) 2022-10-13
BR112022017872A2 (pt) 2022-11-01
CL2022002424A1 (es) 2023-05-05
MX2022010995A (es) 2023-02-27
US20230158015A1 (en) 2023-05-25
IL295824A (en) 2022-10-01
EP4171535A4 (en) 2024-08-21
ZA202209901B (en) 2023-06-28
CA3170998A1 (en) 2021-09-10
AR121523A1 (es) 2022-06-08
TW202139983A (zh) 2021-11-01
JP2023516090A (ja) 2023-04-17
KR20220150371A (ko) 2022-11-10

Similar Documents

Publication Publication Date Title
ZA202307538B (en) Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
BR112014009276A8 (pt) uso de inibidores de tirosina quinase de bruton (btk)
MX2020009773A (es) Terapia de combinacion.
NZ602084A (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
SV2009003283A (es) Inhibidores de la actividad de la akt
MX384721B (es) Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf.
NI201200090A (es) Composiciones para tratar náusea y vómito centralmente mediados
MX391720B (es) Terapia combinada para tratar cáncer.
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MX390121B (es) Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
BR112016000350A8 (pt) métodos de tratamento de lesões inflamatórias da rosácea e usos de uma composição farmacêutica
MX2019013862A (es) Terapia de combinacion.
BRPI0810384B8 (pt) terapia enzimática anticâncer
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
BR112022026247A2 (pt) Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer
MX2025002705A (es) Isoquinolonas como inhibidores de pi3k
MX2020001727A (es) Terapia de combinacion.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CO2022012609A2 (es) Combinaciones de medicamento destinadas a inhibir la inflamación y activación de src quinasa después de procedimientos quirúrgicos invasivos
MX373977B (es) Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos.
MX2024003563A (es) Composicion farmaceutica combinada de inhibidor de cdk4/6 e inhibidor de aromatasa.
BR112015005392A2 (pt) formulação de comprimido de um inibidor de fosfatidilinositol 3-cinase
AR089136A1 (es) Variantes de osteopontina para usar en la supresion o prevencion del crecimiento tumoral y composiciones que las contienen